10.8K(top 3%)
articles
497.4K(top 2%)
citations
4,149(top 2%)
★★ articles
234(top 2%)
★★★ articles
3.5(top 9%)
Avg IF
277(top 2%)
H-Index
492(top 1%)
G-Index
1,451
journals

Most Cited Articles of BC Cancer Agency in 2017

TitleJournalYearCitations
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialLancet, The20171.2K
Integrated genomic characterization of oesophageal carcinomaNature2017965
Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerCell2017961
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialLancet Oncology, The2017706
Association analysis identifies 65 new breast cancer risk lociNature2017643
The whole-genome landscape of medulloblastoma subtypesNature2017472
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate CancerInternational Journal of Radiation Oncology Biology Physics2017419
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal MelanomaCancer Cell2017391
Guidelines for the use of flow cytometry and cell sorting in immunological studiesEuropean Journal of Immunology2017359
Comprehensive Molecular Characterization of Pheochromocytoma and ParagangliomaCancer Cell2017350
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncology, The2017330
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialLancet Oncology, The2017328
Cancer-Associated Mutations in Endometriosis without CancerNew England Journal of Medicine2017310
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancerNature Genetics2017308
ABySS 2.0: resource-efficient assembly of large genomes using a Bloom filterGenome Research2017305
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialAnnals of Oncology2017296
Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancerCancer2017267
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumoursNature Communications2017251
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular ProfilesCell Reports2017247
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypesNature Genetics2017246
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)Annals of Oncology2017241
Non-Hodgkin lymphomaLancet, The2017225
Integrated Molecular Characterization of Uterine CarcinosarcomaCancer Cell2017210
Fate mapping of human glioblastoma reveals an invariant stem cell hierarchyNature2017197
Secondary Somatic Mutations Restoring and Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaCancer Discovery2017193